Lakeshore Biopharma Co. Ltd.
13F holders, Q2 2024 (June 30)11holders +2
4new positions
2sold out
1famous investor
$0.65avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Lakeshore Biopharma Co. Ltd. in their 13F filings, up 2 from Q1 2024. 4 opened new positions and 2 sold out. The largest holders were Orbimed Advisors LLC ($910K), FMR LLC ($755K) and HHLR Advisors, LTD. ($487K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Lakeshore Biopharma Co. Ltd.
- CUSIP
- G9845F109
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $205K |
| Exits | 2 | $4K |
All 13F filers, Q1 2024 → Q2 2024: 449,920 shares bought and 703,404 shares sold, net −253,484 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Orbimed Advisors LLC | 0.02% | Reduce -8.5% | 1,404,280 | $910K |
| FMR LLC | 0.00% | No change | 1,165,071 | $755K |
| HHLR Advisors, LTD. | 0.01% | No change | 751,790 | $487K |
| FIL Ltd | 0.00% | Reduce -39.1% | 733,424 | $475K |
| Bank of Montreal | 0.00% | Reduce -14.9% | 292,704 | $296K |
| Superstring Capital Management LP | 0.25% | No change | 307,920 | $200K |
| Barclays PLC | 0.00% | New | 247,575 | $160K |
| Citadel Advisors | 0.00% | New | 40,675 | $26K |
| Ovata Capital Management Ltd | 0.01% | New | 150,000 | $10K |
| Geode Capital Management, LLC | 0.00% | No change | 13,608 | $9K |
| Susquehanna International Group, LLP | 0.00% | New | 11,670 | $8K |
"% of holder's portfolio" is LAKESHORE BIOPHARMA CO LTD's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.